Aprea Therapeutics, Inc. Stock price

Equities

APRE

US03836J2015

Biotechnology & Medical Research

Delayed Nasdaq 09:57:50 2024-03-28 am EDT 5-day change 1st Jan Change
5.91 USD -2.64% Intraday chart for Aprea Therapeutics, Inc. -6.93% +25.74%
Sales 2024 * 450K Sales 2025 * 450K Capitalization 32.96M
Net income 2024 * -18M Net income 2025 * -22M EV / Sales 2024 * 73.2 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 73.2 x
P/E ratio 2024 *
-1.81 x
P/E ratio 2025 *
-3.36 x
Employees 9
Yield 2024 *
-
Yield 2025 *
-
Free-Float 83.58%
More Fundamentals * Assessed data
Dynamic Chart
Wedbush Raises Aprea Therapeutics' PT to $11 From $9 After Layering In Recent Financing, Maintains Outperform Rating MT
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading MT
Aprea Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Aprea Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Aprea Therapeutics Receives FDA Approval of the IND Application for the Drug Candidate Apr-1051 CI
Aprea Therapeutics, Inc. Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers CI
Aprea Therapeutics, Inc. announced that it expects to receive $16.000005 million in funding from Exome Asset Management LLC, Stonepine Capital Management LLC, Nantahala Capital Management, LLC, Dafna Capital Management, LLC and other company insiders CI
Sector Update: Health Care Stocks Stronger Late Afternoon MT
Aprea Therapeutics Files $150 Million Mixed Shelf; Shares Fall MT
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024 CI
Aprea Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Aprea Therapeutics, Inc. - Special Call
Aprea Therapeutics, Inc. Announces Preclinical Data Supporting Highly Differentiated Wee1 Inhibitor, Atrn-1051, Reliable to Other Wee1 Inhibitors CI
Aprea Therapeutics, Inc. Announces Board Changes CI
Aprea Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
More news

Latest transcript on Aprea Therapeutics, Inc.

1 day+2.53%
1 week-6.62%
Current month-28.25%
1 month-16.51%
3 months+64.05%
6 months+51.00%
Current year+29.15%
More quotes
1 week
5.92
Extreme 5.92
6.31
1 month
5.05
Extreme 5.05
8.85
Current year
4.64
Extreme 4.64
8.85
1 year
2.78
Extreme 2.78
8.85
3 years
2.78
Extreme 2.78
25.80
5 years
2.78
Extreme 2.78
25.80
10 years
2.78
Extreme 2.78
25.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 22-04-30
Director of Finance/CFO 60 23-01-29
Corporate Officer/Principal 62 22-04-30
Members of the board TitleAgeSince
Director/Board Member 67 14-12-31
Director/Board Member 62 19-07-31
Director/Board Member 66 22-04-30
More insiders
Date Price Change Volume
24-03-28 5.91 -2.64% 1 016
24-03-27 6.07 +2.53% 16,742
24-03-26 5.92 -2.69% 10,140
24-03-25 6.084 -0.59% 10,833
24-03-22 6.12 -3.62% 5,207

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing novel synthetic lethality-based cancer therapeutics that target DNA damage response (DDR) pathways. Its synthetic lethality product candidate is ATRN-119, a clinical-stage small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR), a kinase that plays a critical role in DDR. It is targeting WEE1, a kinase that is a key regulator of multiple phases of the cell cycle. Its lead WEE1 inhibitor product candidate is ATRN-1051. In addition, it has a preclinical research program directed at a second-generation ATR inhibitor, ATRN-354. It is also evaluating combination opportunities within its pipeline, including research on the combination of ATRN-119 and ATRN-1051. Its pipeline includes the clinical-stage asset ATRN-119, an ATR inhibitor that is being evaluated in a Phase 1/2a clinical trial in patients with advanced solid tumors having mutations in defined DDR-related genes.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
6.07 USD
Average target price
15.67 USD
Spread / Average Target
+158.10%
Consensus
  1. Stock
  2. Equities
  3. Stock Aprea Therapeutics, Inc. - Nasdaq